Tagged with HIV

UAE 16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses the particularities of the region, and the partnerships and initiatives Gilead is actively pursuing with local stakeholders.   We have…

Africa The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here and part two here). Here, Hwenda examines the persistent challenge of HIV/AIDS…

Africa The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one here) from Lenias Hwenda of Medicines for Africa. Here, Hwenda shines a light on the importance of preventing mother-to-child transmission…

Africa In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of Medicines for Africa shares her personal meditations on the HIV pandemic, the impact of expanded access to antiretroviral therapy, and…

Global The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to, and facilitate the development of, life-saving medicines for low- and middle-income countries. Executive Director Charles Gore outlines the MPP’s goals, how it interacts with an industry – innovative pharma – known to jealously…

Africa While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a huge global issue. It remains highly infectious and difficult to detect in the early stages of infection, while existing treatments are unavailable or too expensive…

Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…

Global In only 21 years, the Global Fund has made remarkable progress in the fight to eliminate HIV, tuberculosis (TB), and malaria across the world, contributing to 44 million lives saved. Cross-sectoral partnerships that leverage the skills and capabilities of governments, multilateral agencies, bilateral partners, civil society groups, people affected by…

Global With several COVID-19 vaccines gaining regulatory approval across the world in record time, a spotlight has been shone on the vaccines field more widely, notably the 30-year wait for a HIV vaccine. Janssen Global Therapeutic Area Head of Vaccines Johan Van Hoof recently sat down with PharmaBoardroom to discuss the…

Norway Christian Probst gives an overview of GSK Norway’s broad portfolio, market access hurdles, and the importance of bringing clinical trials back to Norway. Probst also touches on how the country’s impressive digital footprint can be better leveraged and GSK’s role in Norway as one of the world’s leading vaccine companies.…

Global Dr Johan Van Hoof, global therapeutic area head of vaccines for Janssen, shares his extensive career experience in vaccines; the learnings from Janssen’s Ebola vaccine; and his key message to the global community on vaccines.   We need to be sure we are not complacent. We have to keep an…

Belgium Belgian doctor, researcher and professor, Stéphane De Wit has been with the St Pierre University Hospital in Brussels since 1983. Initially planning to specialize in intensive care, his first internship took him by chance to the infectious diseases department where he encountered his first patients with AIDS, met his mentor,…